Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present GeoVax Labs, Inc. (OTC: GOVX).

Full DD Report for GOVX

You must become a subscriber to view this report.


Recent News from (OTC: GOVX)

GeoVax Reports 2018 First Quarter Financial Results and Development Program Updates
ATLANTA, May 03, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB:GOVX), a biotechnology company developing human vaccines, today announced its financial results for the three months ended March 31, 2018 and provided an update on its vaccine development programs. Robert T. McNally Ph.D.,...
Source: GlobeNewswire
Date: May, 03 2018 13:00
GeoVax to Present its MVA Vector Platform Technology at Vaccinology Conference
ATLANTA, GA, April 19, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that its Chief Scientific Officer, Dr. Farshad Guirakhoo, will be an invited speaker at the 2018 Annual Conference on Vaccinology Research, spo...
Source: GlobeNewswire
Date: April, 19 2018 09:00
GeoVax Awarded NIH Fast Track Phase I/II Grant to Advance Lassa Fever Vaccine
Deadly epidemic continues in Nigeria; Lassa virus remains endemic in West Africa ATLANTA, GA, April 10, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc . (OTCQB: GOVX), a biotechnology company developing innovative human vaccines, announced today that the National Institute of Allergy and...
Source: GlobeNewswire
Date: April, 10 2018 09:00
GeoVax Recognized as "Best Biotech" at Vaccine Industry Excellence Awards during World Vaccine Congress
ATLANTA, GA, April 05, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, is honored to announce that it won “Best Biotech” at the World Vaccine Congress Vaccine Industry Excellence (ViE) Awards. These awards recognize ...
Source: GlobeNewswire
Date: April, 05 2018 09:00
GeoVax Provides Vaccine Development Update
ATLANTA, GA, March 28, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today provided a general update on its various vaccine development programs. Robert McNally, PhD, President...
Source: GlobeNewswire
Date: March, 28 2018 09:00
GeoVax's Chief Scientific Officer to Speak at World Vaccine Congress
GeoVax Also Nominated for Vaccine Industry Excellence Awards Atlanta, GA, March 26, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced that its Chief Scientific Officer, Farshad Guirakhoo, PhD, is an invited speaker at ...
Source: GlobeNewswire
Date: March, 26 2018 09:00
GeoVax Reports 2017 Year-End Financial Results
ATLANTA, March 23, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB:GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for the year ended December 31, 2017. GeoVax reported grant and collaboratio...
Source: GlobeNewswire
Date: March, 23 2018 15:00
Factors of Influence in 2018, Key Indicators and Opportunity within Silver Bull Resources and GeoVax Labs - New Research Emphasizes Economic Growth
NEW YORK, NY / ACCESSWIRE / March 9, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Silver Bull Resources, Inc. (OTCQB: SVBL) and GeoVax Labs Inc. (OTCQB: GOVX), including recent technical analysis and consolidated fundamental information. ...
Source: ACCESSWIRE IA
Date: March, 09 2018 08:30
GeoVax and CaroGen to Collaborate On Development of Therapeutic Hepatitis B Vaccine
Targeting Chronic Hepatitis B Infections Affecting More Than 240 Million People Worldwide ATLANTA, GA, Feb. 07, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc . (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is collaborating with CaroGen Corporat...
Source: GlobeNewswire
Date: February, 07 2018 09:00
GeoVax to Present at the 2018 ASM Biothreats Conference
ATLANTA, GA, Jan. 31, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced that its Chief Scientific Officer, Farshad Guirakhoo, PhD, will deliver a talk, entitled “ From A to Z: Development of Vaccines for AIDS and...
Source: GlobeNewswire
Date: January, 31 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-140.035750.03680.03680.035227,417
2018-08-130.03690.0360.03690.035230,232
2018-08-100.0380.0360.0380.035533,030
2018-08-090.03450.03670.0370.0345736,500
2018-08-080.0350.0360.0370.034185,085

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-14190,135227,41783.6063Short
2018-08-13199,600230,23286.6952Short
2018-08-105,53033,03016.7424Cover
2018-08-09523,030736,50071.0156Short
2018-08-08163,494185,08588.3345Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GOVX.


About GeoVax Labs, Inc. (OTC: GOVX)

Logo for GeoVax Labs, Inc. (OTC: GOVX)

GeoVax Labs, Inc. is a clinical stage biotechnology company developing human vaccines against infectious diseases using our Modified Vaccinia Ankara Virus Like Particle MVA VLP vaccine platform. Our current development programs are focused on preventive vaccines against HIV, Zika virus, Hemorrhagic Fever viruses Ebola, Sudan, Marburg, Lassa , and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. Our vaccine platform supports in vivo production of non infectious VLPs in the person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the ijmmune system to recognize, prevent, and control the target infection.

 

Contact Information

 

 

Current Management

  • David Dodd / Outside Director
  • Robert T. McNally / CEO, President
  • Mark W. Reynolds / CFO, Corporate Secretary
  • Farshad Guirakhoo / Chief Scientific Officer
  • Harriet L. Robinson / Director, R amp D
  • John N. Spencer, Jr. / Outside Director
  • Dean G. Kollintzas / Outside Director
  • Randal D. Chase / Outside Director
  • David Dodd / Chairman
  • Robert T. McNally /
  • Harriet L. Robinson /

Current Share Structure

  • Market Cap: $4,162,736 - 03/09/2018
  • Authorized: 600,000,000 - 12/31/2017
  • Issue and Outstanding: 106,736,810 - 12/31/2017
  • Float: 105,225,604 - 12/31/2017

 


Recent Filings from (OTC: GOVX)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 03 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: May, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Prospectus filed under Rule 424(b)(1)
Filing Type: 424B1Filing Source: edgar
Filing Date: April, 03 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 29 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 23 2018
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: March, 23 2018

 

 


Daily Technical Chart for (OTC: GOVX)

Daily Technical Chart for (OTC: GOVX)


Stay tuned for daily updates and more on (OTC: GOVX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: GOVX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GOVX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of GOVX and does not buy, sell, or trade any shares of GOVX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/